Further adjustments in model 2 included BMI, glycated hemoglobin A1c (HbA1c), uric acid, duration of diabetes, fasting plasma glucose (FPG), dyslipidemia, hypertension, use of lipid-lowering agents, antihypertensive agents, glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, metformin therapy, drinking and smoking status. This evidence concerns the gene GLP1R and metabolic syndrome.